Over the last few decades, the management of stage II and stage III rectal cancer has undergone a gradual evolution towards trimodality therapy (surgery, chemotherapy, and radiotherapy) with the goal of reducing both distant and local–regional recurrence of disease. The combination of optimal surgical technique (total mesorectal excision [TME]) with pelvic radiotherapy and chemotherapy is now a standard form of treatment for patients with rectal cancer.